Global Dexamethasone Sodium Phosphate Injection Market Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2022 to 2028

The global dexamethasone sodium phosphate injection market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). A dexamethasone sodium phosphate injection is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. The global dexamethasone sodium phosphate injection market is growing due to the rising prevalence of arthritis cases globally. According to the Centre for Disease Control and Prevention (CDC), around1 in 4 adults in the US, which accounts for 23.7% or about 58.5 million people have doctor-diagnosed arthritis in 2017.

The rise in eye disorders and eye surgical procedures is also boosting the demand for dexamethasone sodium phosphate injection. According to the article published by the CDC in 2020, around 12 million people of 40 years and above in the US have vision impairment, including 1 million who are blind, 3 million who have vision impairment after correction, and 8 million who have vision impairment due to uncorrected refractive error. According to World Health Organization (WHO) in October 2021, at least 2.2 billion people have a near or distance vision impairment disorder globally.

The rising prevalence of cancer disorder globally and various advancement in treatment to treat the disease is also driving the growth of the global dexamethasone sodium phosphate injection market. According to WHO in February 2022, Cancer is a leading cause of death globally, accounting for around10 million deaths in 2020, or nearly one in six deaths.

The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new drug launches, to stay competitive in the market. For instance-

• In December 2021, the USFDA has granted fast track designation to SP-102 injectable dexamethasone sodium phosphate viscous gel for the treatment of lumbosacral radicular pain, or sciatica.
• In February 2020, Amneal Pharmaceuticals LLC received USFDA approval for the launch of generic dexamethasone sodium phosphate injection, 10 mg/mL.

Market Coverage

• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape-Mylan N.V., Fresenius Kabi AG, and AuroMedics Pharma LLC, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Dexamethasone Sodium Phosphate Injection Market Report by Segment

By Application

• Hospital
• Clinics
• Recovery Centre